To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ombitasvir: Phase II data

The open-label, international Phase II CORAL-I trial in 34 non-cirrhotic, liver transplant patients with recurrent chronic HCV genotype 1 infection showed that AbbVie's all-oral 3D regimen -- comprising co-administration with once-daily 150 mg ABT-450 plus 100 mg ritonavir, once-daily 25

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE